Skip to main content
Erschienen in: International Journal of Hematology 2/2018

03.04.2018 | Original Article

Presepsin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies

verfasst von: Ahmad Baraka, Marwa Zakaria

Erschienen in: International Journal of Hematology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Febrile neutropenia (FN) is often observed in hematological malignancies (HEM). Presepsin is also known as soluble CD14 subtype; it is a glycoprotein fragment derived from monocytes and macrophages. We aimed to evaluate the significance of presepsin and other biomarkers for diagnosis of bacteremia in children with HEM. Sixty pediatric patients with different HEM (acute lymphoblastic leukemia 36, acute myeloid leukemia 12, non-Hodgkin lymphoma 10, and Hodgkin disease 2). Thirty age and sex-matched healthy children serving as control were enrolled in this study. Estimation of presepsin, procalcitonin (PCT), and C-reactive protein (CRP) during episode of FN in addition to absolute neutrophils count (ANC) and blood culture was performed for all the participants. Presepsin levels were higher in the patients than in control with a higher increments in the positive blood cultures than the sterile cases. Presepsin concentration was significantly higher in bacteremia than clinically proved infection and fever of unknown origin. A statistically significant positive correlation between presepsin and CRP plus PCT levels but negative correlation with ANC were observed in the patients subgroups. Presepsin is a useful marker for detection of bacteremia with sensitivity and specificity (100 and 85.7%). This finding supported that presepsin was superior to PCT and CRP in identifying bacterial infection in FN.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Lakshmaiah KC, Malabagi AS, Govindbabu S, Shetty R, Shetty M, Jayashree RS. Febrile neutropenia in hematological malignancies: clinical and microbiological profile and outcome in high risk patients. J Lab Phys. 2015;7(2):116–20. Lakshmaiah KC, Malabagi AS, Govindbabu S, Shetty R, Shetty M, Jayashree RS. Febrile neutropenia in hematological malignancies: clinical and microbiological profile and outcome in high risk patients. J Lab Phys. 2015;7(2):116–20.
2.
Zurück zum Zitat Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v111–8.CrossRefPubMed Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v111–8.CrossRefPubMed
3.
Zurück zum Zitat Villafuerte-Gutierrez P, Villalon L, Losa JE, Henriquez-Camacho C. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. Adv Hematol. 2014;2014:986938.CrossRefPubMedPubMedCentral Villafuerte-Gutierrez P, Villalon L, Losa JE, Henriquez-Camacho C. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. Adv Hematol. 2014;2014:986938.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat El-Mahallawy HA, Hassan SS, El-Wakil M, Moneer MM, Shalaby L. Increasing antimicrobial resistance monitored in surveillance analysis of blood stream infections in febrile neutropenic pediatric oncology patients. Asian Pac J Cancer Prev. 2015;16(14):5691–5.CrossRefPubMed El-Mahallawy HA, Hassan SS, El-Wakil M, Moneer MM, Shalaby L. Increasing antimicrobial resistance monitored in surveillance analysis of blood stream infections in febrile neutropenic pediatric oncology patients. Asian Pac J Cancer Prev. 2015;16(14):5691–5.CrossRefPubMed
5.
Zurück zum Zitat Kim DY, Lee YS, Ahn S, Chun YH, Lim KS. The usefulness of procalcitonin and C-reactive protein as early diagnostic markers of bacteremia in cancer patients with febrile neutropenia. Cancer Res Treat. 2011;43(3):176–80.CrossRefPubMedPubMedCentral Kim DY, Lee YS, Ahn S, Chun YH, Lim KS. The usefulness of procalcitonin and C-reactive protein as early diagnostic markers of bacteremia in cancer patients with febrile neutropenia. Cancer Res Treat. 2011;43(3):176–80.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Qu J, Lu X, Liu Y, Wang X. Evaluation of procalcitonin, C-reactive protein, interleukin-6 & serum amyloid A as diagnostic biomarkers of bacterial infection in febrile patients. Indian J Med Res. 2015;141(3):315–21.CrossRefPubMedPubMedCentral Qu J, Lu X, Liu Y, Wang X. Evaluation of procalcitonin, C-reactive protein, interleukin-6 & serum amyloid A as diagnostic biomarkers of bacterial infection in febrile patients. Indian J Med Res. 2015;141(3):315–21.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother. 2011;17(6):764–9.CrossRefPubMed Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother. 2011;17(6):764–9.CrossRefPubMed
8.
Zurück zum Zitat Arai Y, Mizugishi K, Nonomura K, Naitoh K, Takaori-Kondo A, Yamashita K. Phagocytosis by human monocytes is required for the secretion of presepsin. J Infect Chemother. 2015;21(8):564–9.CrossRefPubMed Arai Y, Mizugishi K, Nonomura K, Naitoh K, Takaori-Kondo A, Yamashita K. Phagocytosis by human monocytes is required for the secretion of presepsin. J Infect Chemother. 2015;21(8):564–9.CrossRefPubMed
9.
Zurück zum Zitat Pugni L, Pietrasanta C, Milani S, Vener C, Ronchi A, Falbo M, et al. Presepsin (soluble CD14 subtype): reference ranges of a new sepsis marker in term and preterm neonates. PLoS ONE. 2015;10(12):e0146020.CrossRefPubMedPubMedCentral Pugni L, Pietrasanta C, Milani S, Vener C, Ronchi A, Falbo M, et al. Presepsin (soluble CD14 subtype): reference ranges of a new sepsis marker in term and preterm neonates. PLoS ONE. 2015;10(12):e0146020.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Bochennek K, Hassler A, Perner C, Gilfert J, Schöning S, Klingebiel T, et al. Infectious complications in children with acute myeloid leukemia: decreased mortality in multicenter trial AML-BFM 2004. Blood Cancer J. 2016;6(1):e382.CrossRefPubMedPubMedCentral Bochennek K, Hassler A, Perner C, Gilfert J, Schöning S, Klingebiel T, et al. Infectious complications in children with acute myeloid leukemia: decreased mortality in multicenter trial AML-BFM 2004. Blood Cancer J. 2016;6(1):e382.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Badiee P, Zareifar S, Haddadi P, Jafarian H. Incidence of fungal infections in pediatric patients with hematologic neoplasms. Arch Pediatr Infect Dis. 2017; e41317 (in press). Badiee P, Zareifar S, Haddadi P, Jafarian H. Incidence of fungal infections in pediatric patients with hematologic neoplasms. Arch Pediatr Infect Dis. 2017; e41317 (in press).
12.
Zurück zum Zitat Olad E, Sedighi I, Mehrvar A, Tashvighi M, Fallahazad V, Hedayatiasl A, et al. Presepsin (Scd14) as a marker of serious bacterial infections in chemotherapy induced severe neutropenia. Iran J Pediatr. 2014;24(6):715–22.PubMedPubMedCentral Olad E, Sedighi I, Mehrvar A, Tashvighi M, Fallahazad V, Hedayatiasl A, et al. Presepsin (Scd14) as a marker of serious bacterial infections in chemotherapy induced severe neutropenia. Iran J Pediatr. 2014;24(6):715–22.PubMedPubMedCentral
13.
Zurück zum Zitat Jimeno A, García-Velasco A, del Val O, González-Billalabeitia E, Hernando S, Hernández R, et al. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer. 2004;100(11):2462–9.CrossRefPubMed Jimeno A, García-Velasco A, del Val O, González-Billalabeitia E, Hernando S, Hernández R, et al. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer. 2004;100(11):2462–9.CrossRefPubMed
14.
Zurück zum Zitat Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients with cancer. Dent Clin N Am. 2008;52(1):61-viii.CrossRef Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients with cancer. Dent Clin N Am. 2008;52(1):61-viii.CrossRef
15.
Zurück zum Zitat Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):427–31.CrossRefPubMed Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):427–31.CrossRefPubMed
16.
Zurück zum Zitat Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, et al. Prespsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care. 2014;18(1):R6.CrossRefPubMedPubMedCentral Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, et al. Prespsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care. 2014;18(1):R6.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Koizumi Y, Shimizu K, Shigeta M, Okuno T, Minamiguchi H, Kito K, et al. Plasma presepsin level is an early diagnostic marker of severe febrile neutropenia in hematologic malignancy patients. BMC Infect Dis. 2017;17:27.CrossRefPubMedPubMedCentral Koizumi Y, Shimizu K, Shigeta M, Okuno T, Minamiguchi H, Kito K, et al. Plasma presepsin level is an early diagnostic marker of severe febrile neutropenia in hematologic malignancy patients. BMC Infect Dis. 2017;17:27.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis. 2005;40(Suppl 4):S240–5.CrossRefPubMed Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis. 2005;40(Suppl 4):S240–5.CrossRefPubMed
19.
Zurück zum Zitat Castagnola E, Fontana V, Caviglia I, Caruso S, Faraci M, Fioredda F, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45:1296–304.CrossRefPubMed Castagnola E, Fontana V, Caviglia I, Caruso S, Faraci M, Fioredda F, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45:1296–304.CrossRefPubMed
20.
Zurück zum Zitat Kitanovski L, Jazbec J, Hojker S, Dergancet M. Diagnostic accuracy of lipopolysaccharide-binding protein for predicting bacteremia/clinical sepsis in children with febrile neutropenia: comparison with interleukin-6, procalcitonin, and C-reactive protein. Support Care Cancer. 2014;22(1):269–77.CrossRefPubMed Kitanovski L, Jazbec J, Hojker S, Dergancet M. Diagnostic accuracy of lipopolysaccharide-binding protein for predicting bacteremia/clinical sepsis in children with febrile neutropenia: comparison with interleukin-6, procalcitonin, and C-reactive protein. Support Care Cancer. 2014;22(1):269–77.CrossRefPubMed
21.
Zurück zum Zitat Rintala E, Irjala K, Nikoskelainen J. Value of measurement of C-reactive protein in febrile patients with hematological malignancies. Eur J Clin Microbiol Infect Dis. 1992;11(11):973–8.CrossRefPubMed Rintala E, Irjala K, Nikoskelainen J. Value of measurement of C-reactive protein in febrile patients with hematological malignancies. Eur J Clin Microbiol Infect Dis. 1992;11(11):973–8.CrossRefPubMed
22.
Zurück zum Zitat Ebihara Y, Kobayashi K, Ishida A, Maeda T, Takahashi N, Taji Y, et al. Diagnostic performance of procalcitonin, presepsin, and C-reactive protein in patients with hematological malignancies. J Clin Lab Anal. 2017;2017:e22147.CrossRef Ebihara Y, Kobayashi K, Ishida A, Maeda T, Takahashi N, Taji Y, et al. Diagnostic performance of procalcitonin, presepsin, and C-reactive protein in patients with hematological malignancies. J Clin Lab Anal. 2017;2017:e22147.CrossRef
23.
Zurück zum Zitat Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother. 2012;18(6):891–7.CrossRefPubMed Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother. 2012;18(6):891–7.CrossRefPubMed
24.
Zurück zum Zitat Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, Forno D, et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Crit Care. 2013;17(4):R168.CrossRefPubMedPubMedCentral Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, Forno D, et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Crit Care. 2013;17(4):R168.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006;34(7):1996–2003.CrossRefPubMed Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006;34(7):1996–2003.CrossRefPubMed
Metadaten
Titel
Presepsin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies
verfasst von
Ahmad Baraka
Marwa Zakaria
Publikationsdatum
03.04.2018
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 2/2018
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-2447-x

Weitere Artikel der Ausgabe 2/2018

International Journal of Hematology 2/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.